Shareholders of ImmunoCellular Therapeutics have voted to implement a reverse stock split at a ratio not less than 1-for-3 and not greater than 1-for-10, according to the results of a special meeting held at the end of June.

The exact ratio will be determined by the company’s board of directors on or before Dec...

Join our Membership to get the full story.


Are you a current Member? Sign In